Detalhe da pesquisa
1.
Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life study.
Dermatol Ther;
35(6): e15489, 2022 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35385202
2.
A linear forehead lesion caused by intralesional injection of triamcinolone acetonide and treated with hyaluronic acid filler: Case report.
Dermatol Ther;
33(6): e14526, 2020 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33174645
3.
Efficacy and safety of adalimumab in difficult-to-treat psoriasis.
Dermatol Ther;
33(3): e13374, 2020 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32246516
4.
Dermoscopic monitoring of efficacy of ingenol mebutate in the treatment of pigmented and non-pigmented basal cell carcinomas.
Dermatol Ther;
30(1)2017 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27860083
5.
Risankizumab: How to choose the right dose in clinical practice?
Dermatol Ther;
33(6): e14371, 2020 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33021745
6.
Ixekizumab: One drug for an enigmatic psoriasis.
Dermatol Ther;
33(6): e13869, 2020 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32558074
7.
Monitoring treatment response in patients affected by actinic keratosis: Dermoscopic assessment and metalloproteinases evaluation after piroxicam 0.8% and sunfilter cream.
Dermatol Ther;
32(1): e12772, 2019 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30318747
8.
Detection of adalimumab and anti-adalimumab levels by ELISA: clinical considerations.
Drug Dev Res;
75 Suppl 1: S11-4, 2014 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25381966
9.
Effectiveness of risankizumab for the treatment of psoriatic arthritis: a multicenter, real-world study.
Int J Dermatol;
2024 Apr 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38584311
10.
Paradoxical case effects of psoriasis following adalimumab therapy: A case series.
Dermatol Ther;
31(6): e12729, 2018 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30239070
11.
Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience.
Drugs Context;
122023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37077769
12.
Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
Dermatology;
225(4): 312-9, 2012.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23295383
13.
Ustekinumab for treatment of plaque psoriasis in a patient with Down syndrome.
J Drugs Dermatol;
11(8): 1000-2, 2012 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22859249
14.
Psoriasis in difficult to treat areas: treatment role in improving health-related quality of life and perception of the disease stigma.
J Dermatolog Treat;
33(1): 531-534, 2022 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32419527
15.
Skin advanced glycation end products as a diagnostic and monitoring tool among psoriatic patients: how the therapy helps reduce cardiovascular disease risk.
Int J Dermatol;
61(5): 577-581, 2022 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34432309
16.
The Effects of Association of Topical Polydatin Improves the Preemptive Systemic Treatment on EGFR Inhibitors Cutaneous Adverse Reactions.
J Clin Med;
10(3)2021 Jan 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33530427
17.
Predictive factors of lack of response to adalimumab among bio-naive patients suffering from moderate-to severe psoriasis: analysis of a multicenter data collection in Italy.
Expert Opin Biol Ther;
21(9): 1291-1298, 2021 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34278889
18.
Omalizumab for chronic spontaneous urticaria in "complex" patients: data from real-life clinical practice.
Drug Des Devel Ther;
13: 3181-3186, 2019.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31564834
19.
Efficacy and safety of adalimumab after failure of other anti-TNFα agents for plaque-type psoriasis: clinician behavior in real life clinical practice.
J Dermatolog Treat;
30(5): 441-445, 2019 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30273075
20.
Long-term treatment of psoriatic patients with adalimumab reduces disease severity and maintains a favorable lipid pattern and a low Atherogenic Index.
G Ital Dermatol Venereol;
153(2): 146-154, 2018 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29564871